Trial Profile

TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Colorectal cancer
Focus Biomarker; Pharmacodynamics; Pharmacogenomic
Acronyms BRAVERY TR

Most Recent Events

24 Sep 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results of translational research of the BRAVERY study presented at the 57th Annual Meeting of the American Society of Clinical Oncology
11 Nov 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com